Comparative efficacy and safety of the non–vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation

K Senoo, GYH Lip - Seminars in Thrombosis and Hemostasis, 2015 - thieme-connect.com
The non–vitamin K antagonist oral anticoagulants (NOACs), such as the thrombin inhibitor
(dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have …
被引用次数：24 相关文章

Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation

K Senoo, GYH Lip - Seminars in Thrombosis and Hemostasis, 2015 - vbn.aau.dk
The non-vitamin K antagonist oral anticoagulants (NOACs), such as the thrombin inhibitor
(dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have …

Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation

K Senoo, GYH Lip - Seminars in thrombosis and …, 2015 - pubmed.ncbi.nlm.nih.gov
The non-vitamin K antagonist oral anticoagulants (NOACs), such as the thrombin inhibitor
(dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have …

Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.

K Senoo, GY Lip - Seminars in Thrombosis and Hemostasis, 2015 - europepmc.org
The non-vitamin K antagonist oral anticoagulants (NOACs), such as the thrombin inhibitor
(dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have …